CB-103
Notch signaling pathway inhibitor / Orally active inhibitor of the Notch signaling activation complex (IC50’s from 0.9 to 3.9 µM in various cell-based assays), the most downstream level of the Notch signaling pathway. It inhibited the growth of Notch-addicted human T cell acute lymphoblastic leukemia cells as well as other cell lines. CB-103 also inhibited the growth of human breast cancer and leukemia xenografts without the intestinal toxicity associated with γ-secretase Notch inhibitors.
Biochemicals & reagents
218457-67-1
Lehal et al. (2020), Pharmacological disruption of the Notch transcription factor complex; Proc. Natl. Acad. Sci. USA, 117 16292
RT
TARGET: Transcription factor -- PATHWAY: Notch; Transcription -- DISEASE AREA: Cancer